AusBiotech is deeply saddened by the loss of Dr Iris Depaz, a long-standing advocate, and champion of Australia’s biotech sector who was known for her visionary leadership and commitment to advancing Australia’s biotech sector.
As an AusBiotech Board Member, Head of Medical Vaccines and Managing Director of the Translational Science Hub in Queensland at Sanofi, Dr Depaz held an unwavering commitment to our sector. She was a hands-on advocate for Australian medical innovation and better health for all Australians. Beyond this, Iris was well known for her warmth, care and compassionate leadership.
Dr Iris Depaz was elected to the AusBiotech Board in November 2023, bringing with her more than 20 years of local, regional and global industry experience, and specialist skills and experience to support growth of Australia’s pharmaceutical and biotech sectors.
“Iris’s positive impact on Australia’s biotech ecosystem will be felt for decades to come,” said Rebekah Cassidy, CEO of AusBiotech.
“Her loss will be heavily felt by our AusBiotech Board and team, and anyone who had the pleasure of knowing her. Iris was not only a strong advocate and leader, but she was also a trusted advisor and dear friend. Our thoughts are with Iris’s family, friends, and close colleagues during this incredibly difficult time.”
Recognising the capability of Australia’s life sciences sector, Iris was deeply passionate about the opportunities investment in the sector could create for Australia as it seeks to diversify its economy and retain the significant talent that exists within our medical and scientific communities.
“Iris was a caring, enthusiastic, and fierce leader, who was passionate about the role Australia should play in the global industry,” said Dr James Campbell, Chair of AusBiotech.
“The AusBiotech Board saw her as a leading light for the sector and someone who deeply cared about advancing industry for the betterment of all Australians. Iris’s loss will have a profound impact on our Board, sector, and all of those who had the good fortune to work with her.”
Iris’s leadership was integral in the development of Sanofi’s Translational Science Hub, a $280 million partnership with the Queensland Government, University of Queensland and Griffith University. One of her key objectives as the Hub’s Managing Director was to enhance the Australian biomedical ecosystem.
Separate to her role at Sanofi, Dr Depaz was a staunch advocate of the power of digital technology and realising opportunities to evolve digital healthcare platforms in Australia. She has previously been a Director of a blockchain and AI start-up, that aimed to empower patients to make informed healthcare decisions via ownership of their own data.
An appropriate tribute will be held at the right time, this will be led by Sanofi who are supporting Iris’s family.
